TY - JOUR
T1 - Image guidance and stabilization for stereotactic ablative body radiation therapy (SABR) treatment of primary kidney cancer
AU - Pham, Daniel T
AU - Kron, Tomas
AU - Bressel, Mathias
AU - Foroudi, Farshad
AU - Hardcastle, Nicholas
AU - Schneider, Michal E
AU - Soteriou, Sally
AU - Innes, Jayson
AU - Siva, Shankar
PY - 2015
Y1 - 2015
N2 - PURPOSE: Stereotactic ablative body radiation therapy for primary kidney cancer treatment relies on motion management that can quantify both the trajectory of kidney motion and stabilize the patient. A prospective ethics-approved clinical trial of stereotactic treatment to primary kidney targets was conducted at our institution. Our aim was to report on specific kidney tumor motion and the inter- and intrafraction motion as seen on treatment. METHODS AND MATERIALS: Patients with tumor size /=5 cm received 42 Gy in 3 fractions. All patients underwent a 4-dimensional computed tomography planning scan, immobilized in a dual-vacuum system. A conventional linear accelerator cone beam computed tomography scan was used for pre-, mid-, and posttreatment imaging to verify target position. RESULTS: Between July 2012 and October 2014, 33 targets from 32 consecutive patients (24 males/8 females) were treated. Seventeen targets were prescribed 26 Gy/1 fraction and the remaining 16 targets received 42 Gy/3 fractions. Kidney motion at each of the poles was not affected by the presence of tumor (P = .875), nor was the motion statistically different from the corresponding contralateral kidney pole (P = .909). The mean 3-dimensional displacement of the target at mid- and posttreatment was 1.3 mm (standard deviation +/- 1.6) and 1.0 mm (standard deviation +/- 1.3), respectively. The maximum displacement in any direction for 95 of the fractions at mid- and posttreatment was
AB - PURPOSE: Stereotactic ablative body radiation therapy for primary kidney cancer treatment relies on motion management that can quantify both the trajectory of kidney motion and stabilize the patient. A prospective ethics-approved clinical trial of stereotactic treatment to primary kidney targets was conducted at our institution. Our aim was to report on specific kidney tumor motion and the inter- and intrafraction motion as seen on treatment. METHODS AND MATERIALS: Patients with tumor size /=5 cm received 42 Gy in 3 fractions. All patients underwent a 4-dimensional computed tomography planning scan, immobilized in a dual-vacuum system. A conventional linear accelerator cone beam computed tomography scan was used for pre-, mid-, and posttreatment imaging to verify target position. RESULTS: Between July 2012 and October 2014, 33 targets from 32 consecutive patients (24 males/8 females) were treated. Seventeen targets were prescribed 26 Gy/1 fraction and the remaining 16 targets received 42 Gy/3 fractions. Kidney motion at each of the poles was not affected by the presence of tumor (P = .875), nor was the motion statistically different from the corresponding contralateral kidney pole (P = .909). The mean 3-dimensional displacement of the target at mid- and posttreatment was 1.3 mm (standard deviation +/- 1.6) and 1.0 mm (standard deviation +/- 1.3), respectively. The maximum displacement in any direction for 95 of the fractions at mid- and posttreatment was
UR - http://www.sciencedirect.com/science/article/pii/S1879850015002866
U2 - 10.1016/j.prro.2015.08.002
DO - 10.1016/j.prro.2015.08.002
M3 - Article
SN - 1879-8500
VL - 5
SP - 597
EP - 605
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 6
ER -
